Raffit Hassan

14.5k total citations · 3 hit papers
184 papers, 9.9k citations indexed

About

Raffit Hassan is a scholar working on Pulmonary and Respiratory Medicine, Biotechnology and Oncology. According to data from OpenAlex, Raffit Hassan has authored 184 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 122 papers in Pulmonary and Respiratory Medicine, 67 papers in Biotechnology and 58 papers in Oncology. Recurrent topics in Raffit Hassan's work include Occupational and environmental lung diseases (115 papers), Cancer Research and Treatments (52 papers) and Pleural and Pulmonary Diseases (38 papers). Raffit Hassan is often cited by papers focused on Occupational and environmental lung diseases (115 papers), Cancer Research and Treatments (52 papers) and Pleural and Pulmonary Diseases (38 papers). Raffit Hassan collaborates with scholars based in United States, Germany and United Kingdom. Raffit Hassan's co-authors include Ira Pastan, Robert J. Kreitman, Anish Thomas, Mitchell Ho, Tapan K. Bera, Jingli Zhang, Beverly A. Teicher, David J. FitzGerald, Masanori Onda and Christine Alewine and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Raffit Hassan

180 papers receiving 9.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

2009 690 citations Raffit Hassan, Ira Pastan et al. profile →
Antibody–drug conjugates for cancer therapy

2016 450 citations Anish Thomas, Raffit Hassan et al. profile →
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline

2018 260 citations Hedy L. Kindler, Nofisat Ismaila et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Raffit Hassan

Since Specialization

Citations

This map shows the geographic impact of Raffit Hassan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raffit Hassan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raffit Hassan more than expected).

Fields of papers citing papers by Raffit Hassan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raffit Hassan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raffit Hassan. The network helps show where Raffit Hassan may publish in the future.

Co-authorship network of co-authors of Raffit Hassan

This figure shows the co-authorship network connecting the top 25 collaborators of Raffit Hassan. A scholar is included among the top collaborators of Raffit Hassan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raffit Hassan. Raffit Hassan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors 2025 ·ESMO Open ·Anna Minchom, O. Lindén, (unknown), Raffit Hassan, Frank I. Lin, (unknown), Vivek Subbiah, Agostino Tafuri, (unknown), (unknown), Adriaan Cleton, (unknown), Friedhelm Bladt, Hartwig Hennekes, Egbert F. Smit	0
2	Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights 2025 ·JCO Oncology Practice ·Hedy L. Kindler, Ibiayi Dagogo‐Jack, Marc de Perrot, Michael W. Drazer, Nofisat Ismaila, Raffit Hassan	0
3	Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas 2024 ·Clinical and Translational Medicine ·(unknown), Abhilash Venugopalan, Jingli Zhang, Nishanth Ulhas Nair, Manjistha Sengupta, Manakamana Khanal, Chaido Stathopoulou, Qun Jiang, Raffit Hassan	3
4	Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors 2022 ·Molecular Cancer Therapeutics ·Sakshi Tomar, Jingli Zhang, Manakamana Khanal, Jessica Hong, Abhilash Venugopalan, Qun Jiang, Manjistha Sengupta, Markku Miettinen, Nan Li, Ira Pastan, Mitchell Ho, Raffit Hassan	31
5	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti–PD-1 antibody in patients with mesothelioma and mouse tumor models 2020 ·Science Translational Medicine ·Qun Jiang, Azam Ghafoor, Idrees Mian, (unknown), Anish Thomas, Christine Alewine, Manjistha Sengupta, Mark A. Ahlman, Jingli Zhang, Betsy Morrow, Seth M. Steinberg, Ira Pastan, Raffit Hassan	35
6	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma 2019 ·Clinical Cancer Research ·Christine Alewine, (unknown), Cody J. Peer, Zishuo I. Hu, Min-Jung Lee, Akira Yuno, (unknown), Anish Thomas, Seth M. Steinberg, Jane B. Trepel, William D. Figg, Raffit Hassan, Ira Pastan	40
7	Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma 2019 ·Clinical Cancer Research ·Raffit Hassan, Evan Alley, Hedy L. Kindler, Scott Antonia, Thierry Jahan, Somayeh Honarmand, Nitya Nair, Chan C. Whiting, Amanda Enstrom, Ed Lemmens, Takahiro Tsujikawa, Sushil Kumar, Gina Choe, Anish Thomas, (unknown), Aimee Murphy, Elizabeth M. Jaffee, Lisa M. Coussens, Dirk G. Brockstedt	88
8	Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM) 2019 ·Journal of Patient-Reported Outcomes ·Tito R. Mendoza, Loretta A. Williams, Karen Keating, Jonathan Siegel, Cem Elbi, Anna K. Nowak, Raffit Hassan, Brian J. Cuffel, Charles S. Cleeland	6
9	Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry 2019 ·American Journal of Industrial Medicine ·Kristin J. Cummings, Michael J. Becich, David J. Blackley, Dennis Deapen, Robert J. Harrison, Raffit Hassan, S. Jane Henley, Mary Hesdorffer, D. Kevin Horton, Jacek M. Mazurek, Harvey I. Pass, Emanuela Taioli, Xiao‐Cheng Wu, Marjorie G. Zauderer, David N. Weissman	10
10	Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients 2018 ·Clinical Cancer Research ·Swati Khanna, (unknown), Francis Mussai, Anish Thomas, Neha Wali, (unknown), Constance M. Yuan, Betsy Morrow, Jingli Zhang, Firouzeh Korangy, Tim F. Greten, Seth M. Steinberg, Maryalice Stetler‐Stevenson, Gary Middleton, Carmela De Santo, Raffit Hassan	43
11	Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline breakdown → 2018 ·Journal of Clinical Oncology ·Hedy L. Kindler, Nofisat Ismaila, Samuel G. Armato, Raphael Bueno, Mary Hesdorffer, Thierry Jahan, Clyde Jones, Markku Miettinen, Harvey I. Pass, Andreas Rimner, Valerie W. Rusch, Daniel H. Sterman, Anish Thomas, Raffit Hassan	260
12	Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response 2016 ·Clinical Cancer Research ·Jingli Zhang, Swati Khanna, Qun Jiang, Christine Alewine, Markku Miettinen, Ira Pastan, Raffit Hassan	30
13	Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors 2015 ·Molecular Cancer Therapeutics ·Ronit Mazor, Jingli Zhang, Laiman Xiang, (unknown), (unknown), Richard Beers, Raffit Hassan, Ira Pastan	33
14	High mesothelin expression in advanced lung adenocarcinoma is associated withKRASmutations and a poor prognosis 2015 ·Oncotarget ·Anish Thomas, Yuanbin Chen, Seth M. Steinberg, Ji Luo, Svetlana Pack, Mark Raffeld, Zied Abdullaev, Christine Alewine, Arun Rajan, Giuseppe Giaccone, Ira Pastan, Markku Miettinen, Raffit Hassan	65
15	Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma 2014 ·Clinical Cancer Research ·Raffit Hassan, Hedy L. Kindler, Thierry Jahan, Lyudmila Bazhenova, Martin Reck, Anish Thomas, Ira Pastan, (unknown), Daniel J. O’Shannessy, (unknown), Julia D. Maltzman, Bruce A. Wallin	139
16	A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity 2012 ·Molecular Cancer Therapeutics ·John E. Weldon, Laiman Xiang, Jingli Zhang, Richard Beers, Dawn A. Walker, Masanori Onda, Raffit Hassan, Ira Pastan	77
17	Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding 2011 ·Cancer Research ·Yujian Zhang, Oleg Chertov, Jingli Zhang, Raffit Hassan, Ira Pastan	39
18	A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake 2010 ·Cancer Research ·Yujian Zhang, Johanna K. Hansen, Laiman Xiang, (unknown), Masanori Onda, Mitchell Ho, Raffit Hassan, Ira Pastan	34
19	Additive anti-tumor effect of Avastin and Immunotoxin combination therapy on tumor-bearing mouse models 2005 ·Cancer Research ·Sookhee Bang, Raffit Hassan, Ira Pastan	1
20	Ex Vivo Cytokine Activation of Peripheral Blood Stem Cells: A Potential Role for Adoptive Cellular Immunotherapy 2001 ·Journal of Hematotherapy & Stem Cell Research ·Kenneth R. Meehan, Aiguo Wu, Raffit Hassan, (unknown), (unknown), Rebecca Slack, Edmund A. Gehan, Herbert B. Herscowitz	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact